Review
Copyright ©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Nov 7, 2008; 14(41): 6289-6297
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6289
Current status of intrahepatic cholangiocarcinoma
Jian Yang, Lu-Nan Yan
Jian Yang, Lu-Nan Yan, Liver Transplantation Division, Department of Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Yang J and Yan LN contributed equally to this work; Yang J and Yan LN designed and performed the research; Yang J wrote the paper.
Correspondence to: Lu-Nan Yan, Liver Transplantation Division, Department of Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. yanlunan688@163.com
Telephone: +86-28-81812453 Fax: +86-28-85423724
Received: March 23, 2008
Revised: September 16, 2008
Accepted: September 23, 2008
Published online: November 7, 2008
Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare primary liver cancer with a global increasing trend in recent years. Symptoms tend to be vague and insidious in development, often are diagnosed at an advanced stage when only palliative approaches can be used with a median survival rate of months. Comparing with HCC, ICC tends to spread to lymph nodes early, and is rarely limited to the regional lymph nodes, with a frequent postoperative recurrence. Surgery is the only choice of curative therapy for ICC, but recently no consensus has been established for operation. Thus, more data from multiple centers and more cases are needed. Generally speaking, current adjunctive therapy cannot clearly improve survival. Further research is needed to find more effective radio- and chemotherapeutic regimens.

Keywords: Intrahepatic cholangiocarcinoma, Lymph node metastasis, Liver transplantation, Adjunctive therapy